CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
MASH
CHOLESTASIS
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees
Embassy of Education
Publications Webcasts Abstract Library
 
PBC Disease Content  
Webcast Library
     
Health-Related Quality of Life and Emerging Therapies In PBC with Paul Kwo, MD, and John Vierling, MD   Educational Webcast
Publications
 
Slide Library
   Released: 2022
test
PBC: Diagnosis and Current Management Strategies
41 slides
 
 
   Released: 2020
test
Clinical Insights Into the Management of Primary Biliary Cholangitis (PBC)
53 slides
 
 
   Released: 2020
test
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments
48 slides
 
 
 
 
 
Abstract Library
1.PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
 

Hepatol Commun. 2024 Dec 20;9(1):e0612. doi: 10.1097/HC9.0000000000000612.eCollection 2025 Jan 1.

Colleen M Hayes 1, Gina M Gallucci 1, James L Boyer 2, David N Assis 2, Nisanne S Ghonem 1
 
2.Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
 

Clin Mol Hepatol. 2024 Nov 11. doi: 10.3350/cmh.2024.0821. Online ahead of print.

Atsumasa Komori 1 2 3, Yuki Kugiyama 2
 
3.Autoimmune Biliary Diseases: A Review of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Immunoglobulin G4-Related Sclerosing Cholangitis, and Autoimmune Hepatitis
 

Surg Clin North Am. 2024 Dec;104(6):1249-1261. doi: 10.1016/j.suc.2024.04.010.Epub 2024 Sep 12.

Suzanne Evans 1, Alana Hofmann 2
 
4.Bidirectional Mendelian randomization links gut microbiota to primary biliary cholangitis
 

Sci Rep. 2024 Nov 16;14(1):28301. doi: 10.1038/s41598-024-79227-z.

Zhijia Zhou 1 2, Wenxuan Li 1 2, Yuelan Wu 1 2, Tao Wang 1 2, Jinghao Zhang 1, Liping You 1, Haoran Li 3, Chao Zheng 4, Yueqiu Gao 5, Xuehua Sun 6
 
5.Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
 

Dig Dis Sci. 2024 Dec 2. doi: 10.1007/s10620-024-08742-w. Online ahead of print.

Nicholas A Cumpian 1, Gina Choi 2, Sammy Saab 3 4
 
6.Therapeutic success in primary biliary cholangitis and gut microbiota: a safe highway?
 

Minerva Gastroenterol (Torino). 2024 Dec;70(4):430-441.doi: 10.23736/S2724-5985.23.03590-8. Epub 2024 Jan 19.

Ludovico Abenavoli 1, Giuseppe Gm Scarlata 2, Emidio Scarpellini 3, Anna C Procopio 2, Francesca R Ponziani 4, Luigi Boccuto 5, Nenad Cetkovic 6, Francesco Luzza 2
 
7.Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design
 

Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174. Online ahead of print.

M Alan Brookhart 1 2, Tracy J Mayne 3, Charles Coombs 4, Alexander Breskin 2, Erik Ness 3, Leona Bessonova 3, Yucheng Julia Chu 3, Jing Li 3, Michael W Fried 2, Bettina E Hansen 5 6 7, Kris V Kowdley 8, David Jones 9, George Mells 10 11, Palak J Trivedi 12, Shaun Hiu 9, Dorcas N Kareithi 9, James Wason 9, Rachel Smith 10, John D Seeger 13, Gideon M Hirschfield 7
 
8.A home-based exercise programme attenuates fatigue in primary biliary cholangitis: Results from the EXCITED clinical trial
 

JHEP Rep. 2024 Sep 6;6(12):101210. doi: 10.1016/j.jhepr.2024.101210. eCollection 2024 Dec.

Alice Freer 1 2, Felicity R Williams 1 2 3, Simon Durman 2, Jennifer Hayden 2, Matthew J Armstrong 1 2, Palak J Trivedi 1 2 4 5
 
9.Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform
 

Commun Med (Lond). 2024 Nov 19;4(1):238. doi: 10.1038/s43856-024-00664-y.

Ruth E Costello 1, Karen M J Waller 2 3 4, Rachel Smith 5, George F Mells 5 6, Angel Y S Wong 7, Anna Schultze 7, Viyaasan Mahalingasivam 7, Emily Herrett 7, Bang Zheng 7, Liang-Yu Lin 7, Brian MacKenna 8, Amir Mehrkar 8, Sebastian C J Bacon 8, Ben Goldacre 8, Laurie A Tomlinson 7, John Tazare 7, Christopher T Rentsch 7 9; OpenSAFELY collaborative; LH&W NCS (or CONVALESCENCE) Collaborative
 
10.Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
 

Clin Mol Hepatol. 2024 Nov 11. doi: 10.3350/cmh.2024.0821. Online ahead of print.

Atsumasa Komori 1 2 3, Yuki Kugiyama 2
 
11.Autoimmune Biliary Diseases: A Review of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Immunoglobulin G4-Related Sclerosing Cholangitis, and Autoimmune Hepatitis
 

Surg Clin North Am. 2024 Dec;104(6):1249-1261. doi: 10.1016/j.suc.2024.04.010.Epub 2024 Sep 12.

Suzanne Evans 1, Alana Hofmann 2
 
12.Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
 

Am J Gastroenterol. 2024 Oct 31. doi: 10.14309/ajg.0000000000003174. Online ahead of print.

Sheena Bhushan 1, Aalam Sohal 1, Kris V Kowdley 1 2, Facg Faasld Agaf 1
 
13.Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity-score matched intention-to-treat registry study
 

Am J Transplant. 2024 Oct 12:S16006135(24)006385. doi:10.1016/j.ajt.2024.10.010.Online ahead of print.

Fredrik Åberg 1, Ville Sallinen 2, Samuli Tuominen 3, Ilkka Helanterä 2, Arno Nordin 2
 
14.Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
 

Cells. 2024 Sep 19;13(18):1580. doi: 10.3390/cells13181580.

Stefano Fiorucci 1, Ginevra Urbani 1, Cristina Di Giorgio 1, Michele Biagioli 1, Eleonora Distrutti 2
 
15.Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
 

JHEP Rep. 2024 Jul 8;6(10):101168. doi: 10.1016/j.jhepr.2024.101168. eCollection 2024 Oct.

Surain B Roberts 1 2 3, Woo Jin Choi 3, Lawrence Worobetz 4, Catherine Vincent 5, Jennifer A Flemming 6, Angela Cheung 7, Karim Qumosani 8, Mark Swain 9, Dusanka Grbic 10, Hin Hin Ko 11, Kevork M Peltekian 12, Lusine Abrahamyan 3 13, Monika Saini 1, Kattleya Tirona 1, Bishoi Aziz 14, Ellina Lytvyak 14, Pietro Invernizzi 15 16, Cyriel Y Ponsioen 17, Tony Bruns 18, Nora Cazzagon 19, Keith Lindor 20, George N Dalekos 21, Nikolaos K Gatselis 22, Xavier Verhelst 23, Annarosa Floreani 19 24, Christophe Corpechot 25, Marlyn J Mayo 26, Cynthia Levy 27, Maria-Carlota Londoño 28, Pier M Battezzati 29, Albert Pares 30, Frederik Nevens 31, Adriaan van der Meer 32, Kris V Kowdley 33, Palak J Trivedi 34 35 36 37, Ana Lleo 38, Douglas Thorburn 13, Marco Carbone 15 16, Nazia Selzner 39, Aliya F Gulamhusein 1 3, Harry LA Janssen 1 32, Aldo J Montano-Loza 14, Andrew L Mason 14, Gideon M Hirschfield 1 3, Bettina E Hansen 1 3 40; Canadian Network for Autoimmune Liver disease (CaNAL)
 
16.Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation
 

J Hepatol. 2024 Oct;81(4):679-689. doi: 10.1016/j.jhep.2024.05.010.Epub 2024 May 29.

Aldo J Montano-Loza 1, Ellina Lytvyak 2, Gideon Hirschfield 3, Bettina E Hansen 4, Maryam Ebadi 2, Thierry Berney 5, Christian Toso 5, Giulia Magini 5, Alejandra Villamil 6, Frederik Nevens 7, Natalie Van den Ende 7, Albert Pares 8, Pablo Ruiz 9, Débora Terrabuio 10, Palak J Trivedi 11, Nadir Abbas 11, Maria Francesca Donato 12, Lei Yu 13, Charles Landis 13, Jérôme Dumortier 14, Jessica Katharine Dyson 15, Adriaan J van der Meer 16, Rozanne de Veer 16, Mark Pedersen 17, Marlyn Mayo 17, Michael P Manns 18, Richard Taubert 19, Theresa Kirchner 19, Luca S Belli 20, Chiara Mazzarelli 20, Guido Stirnimann 21, Annarosa Floreani 22, Nora Cazzagon 22, Francesco Paolo Russo 22, Patrizia Burra 22, Udi Zigmound 23, Inbal Houri 23, Marco Carbone 24, Giacomo Mulinacci 24, Stefano Fagiuoli 25, Daniel Stephan Pratt 26, Alan Bonder 27, Thomas D Schiano 28, Brandy Haydel 28, Ansgar Lohse 29, Christoph Schramm 30, Darius Rüther 29, Stefania Casu 31, Xavier Verhelst 32, Benedetta Terziroli Beretta-Piccoli 33, Mercedes Robles 34, Andrew L Mason 2, Christophe Corpechot 35; Global PBC Study Group
 
17.Predictors of survival in autoimmune liver disease overlap syndromes
 

World J Hepatol. 2024 Sep 27;16(9):1269-1277. doi: 10.4254/wjh.v16.i9.1269.

Dujinthan Jayabalan 1 2, Yi Huang 3, Luis Calzadilla-Bertot 1 3, Malik Janjua 3, Bastiaan de Boer 4, John Joseph 4, Wendy Cheng 5, Simon Hazeldine 6, Briohny W Smith 3, Gerry C MacQuillan 1 3, Michael C Wallace 1 3, George Garas 1 3, Leon A Adams 1 3, Gary P Jeffrey 1 3
 
18.Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy
 

Hepatology. 2024 Oct 1;80(4):791-806.doi: 10.1097/HEP.0000000000000826. Epub 2024 Mar 6.

Javier Ampuero 1 2 3 4, Ana Lucena 1, Marina Berenguer 4 5 6, Manuel Hernández-Guerra 7, Esther Molina 8, Judith Gómez-Camarero 9, Carlos Valdivia 4 10, Elena Gómez 11, Marta Casado 12, Carmen Álvarez-Navascuez 13, Francisco Jorquera 4 14, Luisa García-Buey 15, Álvaro Díaz-González 16, Rosa Morillas 4 17 18, Montserrat García-Retortillo 19, Jose M Sousa 1, Indhira Pérez-Medrano 20, Miguel Á Simón 4 21 22, Javier Martínez 4 23, Juan Arenas 24, María Carlota Londoño 4 25, Antonio Olveira 26, Conrado Fernández-Rodríguez 27; ColHai Registry
 
19.Primary biliary cholangitis
 

Lancet. 2024 Sep 14;404(10457):1053-1066. doi: 10.1016/S0140-6736(24)01303-5.Epub 2024 Aug 28.

Atsushi Tanaka 1, Xiong Ma 2, Atsushi Takahashi 3, John M Vierling 4
 
20.Elafibranor: First Approval
 

Drugs. 2024 Aug 7. doi: 10.1007/s40265-024-02075-8. Online ahead of print.

Hannah A Blair 1
 
21.Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
 

Expert Opin Pharmacother. 2024 Aug 6. doi: 10.1080/14656566.2024.2390120.Online ahead of print.

Allyce Caines 1 2, Sheri Trudeau 3, Stuart C Gordon 1 4
 
22.COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls
 

Am J Gastroenterol 2024 Aug 14. doi: 10.14309/ajg.0000000000003029. Online ahead of print.

Kris V Kowdley 1, Gideon M Hirschfield 2, Charles Coombs 3, Elizabeth S Malecha 4, Leona Bessonova 4, Jing Li 4, Nuvan Rathnayaka 5, George Mells 6, David E Jones 7, Palak J Trivedi 8, Bettina E Hansen 9 10 11, Rachel Smith 12, James Wason 7, Shaun Hiu 7, Dorcas N Kareithi 7, Andrew L Mason 13, Christopher L Bowlus 14, Kate Muller 15, Marco Carbone 16, Marina Berenguer 17, Piotr Milkiewicz 18 19, Femi Adekunle 20, Alejandra Villamil 21
 
23.Why are rare diseases underdiagnosed? A clinical management study on detection of primary biliary cholangitis in primary care
 

Ann Ig. 2024 Sep-Oct;36(5):614-618. doi: 10.7416/ai.2024.2629.

Francesco Donato 1, Marie Graciella Pigozzi 1, Giulia Colarieti 1, Marco Festa 1, Erminio Tabaglio 2 3
 
24.Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat
 

Liver Int. 2024 Sep;44(9):2293-2302. doi: 10.1111/liv.15982. Epub 2024 May 23.

Eleni Karatza 1, Brandon Swift 2, Fernando Carreño 3, Sumanta Mukherjee 3, Linda Casillas 3, Janelle Lennie 3, James Fettiplace 4, Megan M McLaughlin 3, Andreas E Kremer 5
 
25.Why are rare diseases underdiagnosed? A clinical management study on detection of primary biliary cholangitis in primary care
 

Ann Ig. 2024 Sep-Oct;36(5):614-618. doi: 10.7416/ai.2024.2629.

Francesco Donato 1, Marie Graciella Pigozzi 1, Giulia Colarieti 1, Marco Festa 1, Erminio Tabaglio 2 3
 
View More
 
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

MASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2025 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.